A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
Florian Büttner(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Elke Schaeffeler(German Cancer Research Center)
Cited by 29
Related Papers
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
|The Lancet|2023|508